Mitochondrial and postmitochondrial survival signaling in cancer

Neelu Yadav1, Dhyan Chandra1

  • 1Department of Pharmacology Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, United States.

Mitochondrion
|December 17, 2013
PubMed

Insights

Cancer cells resist therapy through complex survival mechanisms involving mitochondria. Understanding the crosstalk between pro-survival and pro-death molecules is key to developing new cancer treatments.

Area of Science:

  • Mitochondrial biology
  • Cancer cell biology
  • Molecular mechanisms of disease

Background:

  • Cancer cells exhibit resistance to conventional chemotherapy and radiotherapy.
  • The precise molecular mechanisms underlying therapeutic resistance in cancer remain incompletely understood.
  • Cellular machinery protects mitochondrial integrity against various stresses, influencing cancer cell survival.

Purpose of the Study:

  • To explore the intricate crosstalk between prosurvival and prodeath molecules.
  • To elucidate how this molecular crosstalk regulates mitochondrial functions and enhances cancer cell survival.
  • To identify putative survival mechanisms at the mitochondria for designing effective cancer therapies.

Main Methods:

  • This is a review article, synthesizing existing research.
  • Analysis of molecular pathways regulating mitochondrial integrity and apoptosis.
  • Exploration of the interplay between pro-survival and pro-death signaling in cancer.

Main Results:

  • Prodeath molecules, while initiating cell death, also contribute to cancer cell survival.
  • Prosurvival mechanisms operate at both mitochondrial and postmitochondrial levels to counteract apoptosis.
  • The crosstalk between these molecular players dictates cancer cell fate and therapeutic response.

Conclusions:

  • Mitochondrial survival pathways are critical targets for novel cancer prevention and therapy development.
  • Understanding these mechanisms can lead to more effective anti-cancer agents.
  • These pathways may also be relevant to other diseases like diabetes and neurodegeneration.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

3.8K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
11.9K